Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Well IF that anchor/conman/ proven swindler / is cut away like the cancer he is. Better for longs here. But look to the issues of structure here. It's a set up and venture capital folks will be wiped out in reality.
I’m pretty sure there was an 8-K in the last month or two stating that the company has a new CFO… and that Nelson is no longer with the company. I’ll see if I can find it.
Randy, isn’t Nelson still with QSAM? You mentioned that he is no longer with the company? We’re you speaking of QSAM or another company?
I’ve been watching and even advocating for this company for a while.
Your criticism of the company is only partly accurate… I understand that you and Chuck and other investors lost money with Chris Nelson and Kevin Bolin at the helm. Did they intentionally try to make the company fail? I doubt it.
What you don’t seem to have noticed is that both Bolin and Nelson are no longer with the company. Bolin was never a part of the reorganized company and Chris Nelson stayed on for just a year or so after the company was acquired by new management.
QSAM is a completely different entity than it has been before. Have you checked out their web page?
https://qsambio.com/#about
Check out the projects and potential they have:
https://ir.qsambio.com/
Have you read the bios of the folks involved?
https://ir.qsambio.com/company-information/management-team
These guys have successfully done this before. Have they reversed the previous shareholders to minimal levels? Sure. Did that affect me? Obviously. But that has undoubtedly affected Bolin and Nelson as well. You’ll probably enjoy knowing that at least a little.
My perspective might be simplistic, but the future success of the company is another matter. As an entity it is now making decisions that will hopefully allow those involved to bring a new drug to market AND hopefully provide a sizable return to those who have funded the venture…. the venture capitalists.
Proof of this, management‘s recent decision to walk away from a poorly structured VC offer. They didn’t like the terms even though it would have allowed them to uplist to NASDAQ. From what I can gather, they expect good outcomes from their drug trials and they will then be in a stronger negotiating position.
At this point, the only way for the investing public to participate in QSAM’s potential future success is to purchase shares in the open market… or possibly participate in some future share offering of it becomes available to the public.
I hear crickets and crashing. mmmmmmmmm
Hello. Anybody watching this pump and dump? Currently crashed down another 23% on 4 times avg. vol. Will It get pumped back on air? Or punish anyone who sells on down lower? All scammy.
Still fresh today. see dates of Chucks accurate post.
IMAC is a winner in this space. qsam is a swindal pump and dump keeping commons trapped.
GREETINGS!! well kids currently crashed down 15%. Yesterday was worse. After 40 for 1 second reverse split by chris nelson and qsam. Well this is EXACTLY HOW A PUMP AND DUMP WORKS!! regards. glta. PEACE
HOWDY !!! CURRENTLY CRASHED DOWN ONLY 29%. after the 1 for a million rev. split. slight exag. lol pump and dump. investors stay trapped=bagholder.
Hey Chuck...good post. so currently this pump and dump is down by 1/3 total value.....after that 2nd 1for40 rev. split. wow scam is good for insiders. glty
Hey Bobby don't forget, this is the second reverse split since Nelson took control of the shell. The first was 7 to 1...
So actual current price is $0.023 for those who fell into this at the start.
-Chuck
ok OK 1 share given....40 taken RS. You were warned by me and Chuck. Now down 10%. This will never profit anyone but insiders. It's a stock selling scam. Just like chris nelson on cypw now defunct and gone $70 million taken. $0 given. SSDD
QSAM Biosciences, Inc. – Follow-On Offering
Issuer:
QSAM Biosciences, Inc.
Listing:
Current Listing: OTCQB: QSAMD
Listing on Nasdaq under the ticker symbol: QSAM
Expected Offering Size:
Approximately $20,000,000
Over-Allotment Option:
15% (100% Primary)
Expected Timing
March 24th
Sole Book-Runner:
ThinkEquity
Business Summary:
QSAM Biosciences, Inc. is developing next-generation nuclear medicines for the treatment of cancer and related diseases. The Company’s initial technology is Samarium-153 DOTMP, a/k/a CycloSam® (“CycloSam®” or the “New Technology”), a clinical-stage bone targeting radiopharmaceutical. CycloSam® features a patented, low specific activity form of Samarium-153, a beta-emitting radioisotope with a short 46-hour half-life, and the chelating agent DOTMP, which selectively targets sites of high bone mineral turnover and reduces off-site migration of the tumor-killing radiation.
Link to Preliminary Prospectus Supplement, filed with the SEC on March 10, 2022: https://www.sec.gov/ix?doc=/Archives/edgar/data/1310527/000149315222006465/forms-1a.htm
QSAM one for 40 reverse split:
https://otce.finra.org/otce/dailyList?viewType=Symbol%2FName%20Changes
$QSAM Very big step today. Priority Review Vouchers, if obtained, are typically with north of $100M. Current market cap is $13M. Way undervalued here.
I understand your negative bias. Losing money leaves a bread taste in your mouth. Fool me once shame on you; fool me twice shame on me. Maybe I’m naive, but in this case, the facts seem overwhelming.
My bias is in favor of the story and potential that’s pretty plain to see. This is no longer Chris Nelson’s show. His interest is largely from debt conversion and amounts to 4.9%. Other management and insiders own just over 53.5% of the company.
It seems to me he’s made connections with some pretty successful people and provided himself and other investors with a remarkable opportunity.
What do we know?
1. Management has a track record of success. Check out co-founders Douglas Baum and C.Richard Piazza’s bios. Then look up Link, Sugarman, Frank, and Simon. What’s not to love?
Just check out their website. https://qsambio.com/
Then compare the management/ insider ownership here: https://www.otcmarkets.com/filing/html?id=15429489&guid=OhvwkaoGobwyOth
2. Venture capitalists have been willing to commit substantial resources to the future success of the company. I've not added up the totals but I think it's between $3 and 5$ Million.
3. We have an actual drug with a proven history of effective treatment of bone cancer.
4. We have a drug in Phase 1 FDA Trial… that is really an improved drug with fewer side effects.
5. The value of the company surpasses the current drug candidate. QSAM has an exclusive license agreement on any future drugs or treatment protocols developed by IGL Pharma, Inc, the maker or developer of Samarium-153 DOTMP, known as CycliSam.
Will all this end with success or failure? Time will tell.
A reverse split of 20:1 would be required to get the price to a level where up listing would be possible.
Its another pipe dream that has been sold on every stock ticker Chris Nelson has been associated with over the past 20 years. The reality is that the share price will continue its downward trend and up listing will never materialize.
-Chuck
I believe they stated that the reverse would only take place if it was in conjunction with uplisting to the NASDAQ Capital Market or for a listing the NYSE.
Maybe it goes down because of such uplisting... but generally, this is regarded as a positive step.
Cheers.
Reverse split to get the share price higher, then authorize more shares to dilute... SOP of Chris Nelson.
$0.001 coming soon
-Chuck
Hi Randy,
Sheesh. This along with SPYR. Thanks for the news, I guess.
Management Authorized to do reverse split in conjunction with qualifying for NASDAQ Capitol Market or NYSE Listing
https://www.otcmarkets.com/filing/html?id=15467011&guid=faSwkpl1u7CdB3h
Down on a 100,000+ share trades.. back up on a 5,000 trade.
Sure sign of dumping.. this is the toxic debt shares being sold for whatever price they can get for them. This will continue on and on until its sub penny.
It is the Chris Nelson way...
-Chuck
MARKETS AT RECORD HIGHS. this just lost 1/3rd. 32% crash. But hey reminder cypw chris got that scam on the QB board also. QB stands for qualifying board. It's just 1 step in proving this is even a real company. And last look up what it takes to qualify to the Nasdaq. This is many levels away from such lofty speak. But cons like Chris Nelson is an expert con atty. a penny stock pinks wizard.
Bragging and conning. Remember he was " gonna bring back to USA the LSR record. He took Millions. Car never moved on it's own. Not 1 foot. Investors lost $70 MILLION. composting was his true calling. all BS 24/7 365. PERIOD
Thanks for posting… I hadn’t seen this. I’ve been a QSAM fan since the reorganization.
4:57 pm ET *DJ QSAM Biosciences, Now on OTCQB Venture Market, Files for Stock Offering and Seeks Listing on Nasdaq Capital Market(Dow Jones)
Guess that means we are officially have a dog in Phase 1 of its development!!
QSAM Biosciences Activates Clinical Sites and Opens Enrollment for its Phase 1 Clinical Trial of CycloSam® for the Treatment of Bone Cancer
https://finance.yahoo.com/news/qsam-biosciences-activates-clinical-sites-140000294.html
"The initiation of our first Phase 1 clinical trial of CycloSam is an important development for QSAM as it demonstrates the potential for treating bone cancers using our new approach. We look forward to driving enrollment forward and establishing a safety profile and understanding of CycloSam’s potential for efficacy,” stated Douglas R. Baum, QSAM’s CEO.
Looks like they just sold off $555,000 of debit... with another $445,000 remaining..
There is a difference between not being successful at a venture and setting a venture up to not be successful from the start.
QSAM is the latest front for this scheme after CYPW failed, Q2P failed, Q2E failed... Failed is just an opinion because in reality in each of those instances Chris Nelson lined his pockets with cash. It was only the small investors that failed!
-Chuck
Must have been the other mod then. Only 3 of us have the ability to edit that information.
Chris Nelson as CFO?? But he is "General" Nelson! He is a lawyer by education, he is not doing the accounting.
He is in charge of raising capital, he is one of the owners of the stock shell.... He is the real owner and the man behind the curtain.
What you should be asking is who is:
Your theory is pretty clear. Chris Nelson is a scam artist that is only interested in making money from unwary investors.
I don't believe that is the case. Has he been unsuccessful in the past? Yes... but such is the case. I've posted before that those who have taken ventures and pursued success are more likely to continue trying until they succeed.
I believe QSAM is the latest phase in this attempt for success.
I would assume at some point the information will be clear who owns what percent of the Company. I will be surprised if Mr. Melson owns more than 10-15% of the new company. We will have to wait to see.
So yes... the previous company has been rescued... but it has continued pursuing a business venture that seems to have a reasonable possibility of success.
According to your thinking... maybe they should have just put up the white flag and given up. And yet, how would have that helped... what good could come from ceasing to exist?
The direction they've gone has garnered significant investment from those closest to the company. Prior debt holders have received equity interest. I believe at this point the company is debt-free, but I'm not certain.
On top of this, I think the company has received venture Capital Funding in the millions of dollars, which means that those whose who know more than me... and possibly more than you are putting their money where their mouth is... have voted with their dollars on the future success of QSAM.
Plus if you look at the leadership page... the man who invented "Quadramet" is on the company's advisory board. I don't doubt that he knows very well the functional success anticipated on our first orphan drug candidate... "Cyclosam."
I have no idea what you're talking about. I'm not sure how I could remove anyone from the board.
All I did was cut and paste the information available on the https://qsambio.com/#about website...
and the management page that listed the company officers.
https://qsambio.com/#leadership
Chairman of the Board of Directors: C. Richard Piazza
Chief Executive Officer: Douglas R. Baum
Chief Medical Director: Dr. Charles G. Link
Senior Executive Generalist: Barry Sugarman
What role does the "villain" Chris Nelson have? He is the CFO... the Chief Finanical Officer. HE does the accounting... and reporting of the business that has taken place.
And what has become of the other person from the past... Kevin Bolen? Well he's gone. He took some equity interest and is no longer with the company.
I see you removed the Chris Nelson information from the board... why? Don't want people to know who is really behind this?
You can make any story seem positive if you only show the positive aspects. To know the truth, you need the entire story.. good/bad/ugly...
-Chuck
Randy,
Cyclone also had what seemed like a very strong leadership team, but in reality these people were not involved with the business at all with the exception of receiving stock as a form of payment for using their name.
Good stuff Randy. I spoke with Chris Nelson last week. Seemed up beat.
Said they expect Phase 1 trial to begin in January.
I think he said they have 17 patients.
Trials to last about a year.
Gave some comps. Microbot (MBOT), Quadramet???? and Fusion (FUSN). Pretty healthy market cap (for FSUN- $300M) and in a similar stage of growth as QSAM I believe.
My notes are sketchy, he talks fast..lol.
Anyway some DD on these might give some insight as to what we can expect.
cheers
WAIT... THERE'S MORE!! R.KEITH FRANK
Over 30 years experience each with Dow Chemical leading R&D efforts in Radiopharmaceuticals & Chelators
Developed Quadramet®
Founded IsoTherapeutics in 2005 performing contract R&D for Big Pharma with emphasis on radiolabeling
Authored/co-authored more than 100 scientific papers & publications
Recognized as leading authorities in radiopharmaceuticals
60+ Patents
Internationally recognized experts in radiopharmaceuticals
Extensive interaction with research institutions, investigators and hospitals
Any Slouches? nope NOT HERE>>> Barry Sugarman is a Senior Executive Generalist with over 30 years of experience spanning public and private companies in the pharmaceutical, medical device, dietary supplement, and cosmetic industries. Barry has considerable direct experience in pharmaceutical product development, manufacturing, clinical trials, regulatory affairs, FDA and government relations, marketing, and distribution.
Barry possesses broad experience in clinical trial operations and management, mergers, acquisitions, turnarounds, startups, reorganization, process improvements, and sales management and a very strong knowledge of Good Manufacturing Practices (GMP’s), Good Clinical Practices (GCP’s), Good Laboratory Practices (GLP’s), and International Conference for Harmonization (ICH) requirements. He is an author and co-author of numerous FDA filings and approvals including Investigational New Drug Applications (IND’s), New Drug Applications (NDA’s), Abbreviated New Drug Applications (ANDA’s), and Medical Device Applications 510(k)’s.
Barry is a member of the Regulatory Affairs Professional Society (www.raps.org), American Association of Pharmaceutical Scientists (www.aaps.org), Association of Clinical Research Professionals (www.acrpnet.org), and the National Association of Corporate Directors (www.nacdonline.org). He is a co-author of “Prompt, Accurate Diagnosis of Pediatric Cancer and Leukemia for Pediatricians, Orthopedists, and Family Practitioners” – Paperback (Aug. 28, 2007) by Andrew Pendleton, Jennifer Minigh, Lainie Shapiro, and Barry Sugarman.
Yes, there's more... Dr. Charles J Link is an accomplished physician scientist and experienced executive with decades of biotech and drug development experience. Previously, Dr. Link founded NewLink Genetics, a NASDAQ-listed immunotherapy company focused on developing novel immuno-oncology product candidates. He served as Chairman, CEO and Chief Scientific Officer of NewLink Genetics until his retirement in 2019. During his tenure at NewLink, Dr. Link led a series of collaborative transactions totaling hundreds of millions of dollars with Merck, Roche and the United States government. He also supervised the collaboration between NewLink and Merck to develop EVERBO, the first and only Ebola vaccine to receive FDA and EMA approval.
Dr. Link has been a practicing oncologist for over 30 years and has authored more than 150 peer-reviewed papers. He is inventor on numerous patents in the field of cancer immunotherapy.
Want some more talent... well here's more: C. Richard Piazza, Ph.D. is a career healthcare executive with 48 years of experience in medical devices as well as the pharmaceutical/biotechnology sectors. Included in this is 44 years in general management positions in both public and private international companies including Ohmeda, Smith & Nephew Pharmaceuticals, Marquest & VitaGen (world’s first bioartifical liver). In 2019 he co-founded QSAM Therapeutics, Inc. with Doug Baum and currently serves as its Executive Chairman.
For Example: Douglas R. Baum has 28+ years of experience serving in a number of executive management and business development positions within the drug development and life sciences industries. Currently, he serves as the CEO, President and Director of QSAM and its subsidiary, QSAM Therapeutics, Inc., a company he co-founded in 2019. QSAM is an Austin, Texas based clinical stage specialty pharmaceutical company developing a pipeline of radiopharmaceuticals focused on various bone and solid tumor cancers.
The website details the new officers and board members. Since these men have been successful in the past, I believe there is a great likelihood they will be successful in the future.
https://qsambio.com/#leadership
If you visit QSAM's website and read what they've accomplished and what they intend to do... I think it's looking like they're positioning themselves as a buyout target within the next 1-3 years.
https://qsambio.com/#about
I've been with QSAM for the last couple of years. The only part of the former company that remains is the CFO... Mr. Chris Nelson. In my estimation, even though there is mostly new management and wholly new business direction company, the company retained Mr. Nelson because of his familiarity with the companies history and organization.
Decided to re-establish a position in QSAM. I bought a chuck of the 28 cent offers last week.
While the naysayers think QSAM is just another revision of previous companies, QSAM's management is loaded with heavy hitters that fully intend to add value and sellable products to the public.
Followers
|
14
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
933
|
Created
|
01/15/08
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |